ReviewFrontiers in immunology2026
Evidence for microvesicle particles and platelet-activating factor as effectors for systemic effects of thermal burn injury.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Thermal burn injury (TBI) is an important source of morbidity and mortality. The exact mechanisms for the systemic effects including multiple organ dysfunction (MOD) and immune deficits associated with extensive skin burn injuries are unclear and this knowledge gap has negatively impacted therapy. The goal of this review is to present evidence for a model of TBI-induced systemic effects that involves skin keratinocyte release of subcellular microvesicle particles (MVP) carrying the potent lipid mediator Platelet-activating Factor (PAF) as effectors. As TBI has been shown to generate high levels of potent 1-alkyl PAF versus lesser amounts of inhibitory 1-acyl PAF species, it would be expected that MVP produced by burn would be highly powerful PAF receptor agonists. In addition, we present results of a pilot study with 12 human subjects suggesting that MVP can be measured systemically within hours following a TBI. This model involving MVP provides an explanation for why advanced age and ethanol intoxication result in worsening systemic effects including MOD following a TBI. The need for more clinical studies in this critical area of TBI pathogenesis is also discussed. Potential therapeutic implications of this model will also be addressed. An improved understanding of how a significant skin burn injury results in systemic manifestations will result in improved TBI patient outcomes and could be applicable to other environmental stressors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.